BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 14770374)

  • 1. [Gene therapy of children with X-linked severe combined immune deficiency: efficiency and complications].
    Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
    Med Sci (Paris); 2004 Jan; 20(1):115-7. PubMed ID: 14770374
    [No Abstract]   [Full Text] [Related]  

  • 2. Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position of the European Society of Gene Therapy (ESGT).
    Gansbacher B;
    J Gene Med; 2003 Mar; 5(3):261-2. PubMed ID: 12666192
    [No Abstract]   [Full Text] [Related]  

  • 3. French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy.
    European Society of Gene Therapy
    J Gene Med; 2003 Jan; 5(1):82-4. PubMed ID: 12516054
    [No Abstract]   [Full Text] [Related]  

  • 4. Occurrence of leukaemia following gene therapy of X-linked SCID.
    Kohn DB; Sadelain M; Glorioso JC
    Nat Rev Cancer; 2003 Jul; 3(7):477-88. PubMed ID: 12835668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy for severe combined immune deficiency.
    Qasim W; Gaspar HB; Thrasher AJ
    Expert Rev Mol Med; 2004 Jul; 6(13):1-15. PubMed ID: 15236670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.
    Hacein-Bey-Abina S; von Kalle C; Schmidt M; Le Deist F; Wulffraat N; McIntyre E; Radford I; Villeval JL; Fraser CC; Cavazzana-Calvo M; Fischer A
    N Engl J Med; 2003 Jan; 348(3):255-6. PubMed ID: 12529469
    [No Abstract]   [Full Text] [Related]  

  • 7. Gene therapy. Second child in French trial is found to have leukemia.
    Marshall E
    Science; 2003 Jan; 299(5605):320. PubMed ID: 12531981
    [No Abstract]   [Full Text] [Related]  

  • 8. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.
    McCormack MP; Rabbitts TH
    N Engl J Med; 2004 Feb; 350(9):913-22. PubMed ID: 14985489
    [No Abstract]   [Full Text] [Related]  

  • 9. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.
    Hacein-Bey-Abina S; Le Deist F; Carlier F; Bouneaud C; Hue C; De Villartay JP; Thrasher AJ; Wulffraat N; Sorensen R; Dupuis-Girod S; Fischer A; Davies EG; Kuis W; Leiva L; Cavazzana-Calvo M
    N Engl J Med; 2002 Apr; 346(16):1185-93. PubMed ID: 11961146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome].
    Fischer A; Hacein-Bey-Abina S; Lagresle C; Garrigue A; Cavazana-Calvo M
    Bull Acad Natl Med; 2005 May; 189(5):779-85; discussion 786-8. PubMed ID: 16433450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy: therapeutic gene causing lymphoma.
    Woods NB; Bottero V; Schmidt M; von Kalle C; Verma IM
    Nature; 2006 Apr; 440(7088):1123. PubMed ID: 16641981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy fulfilling its promise.
    Kohn DB; Candotti F
    N Engl J Med; 2009 Jan; 360(5):518-21. PubMed ID: 19179320
    [No Abstract]   [Full Text] [Related]  

  • 13. Gene therapy for severe combined immunodeficiency disease.
    Handgretinger R; Koscielniak E; Niethammer D
    N Engl J Med; 2002 Aug; 347(8):613-4; author reply 613-4. PubMed ID: 12192024
    [No Abstract]   [Full Text] [Related]  

  • 14. [Gene therapy for severe combined immunodeficiency].
    Petersen LB; Jensen TG
    Ugeskr Laeger; 2010 Jun; 172(23):1756-8. PubMed ID: 20534204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy put on hold as third child develops cancer.
    Check E
    Nature; 2005 Feb; 433(7026):561. PubMed ID: 15703711
    [No Abstract]   [Full Text] [Related]  

  • 16. Safeguards for gene therapy trials.
    FDA Consum; 2003; 37(3):5. PubMed ID: 12793378
    [No Abstract]   [Full Text] [Related]  

  • 17. Gene therapy. As Gelsinger case ends, gene therapy suffers another blow.
    Couzin J; Kaiser J
    Science; 2005 Feb; 307(5712):1028. PubMed ID: 15718439
    [No Abstract]   [Full Text] [Related]  

  • 18. [Setback for gene therapy: Two cases of leukemia in a French trial].
    Richter J; Relander T; Fasth A; Karlsson S
    Lakartidningen; 2003 Feb; 100(7):498-500. PubMed ID: 12640983
    [No Abstract]   [Full Text] [Related]  

  • 19. Temporary halt on gene therapy trials.
    FDA Consum; 2003; 37(2):6. PubMed ID: 12715756
    [No Abstract]   [Full Text] [Related]  

  • 20. Gene therapy: X-SCID transgene leukaemogenicity.
    Thrasher AJ; Gaspar HB; Baum C; Modlich U; Schambach A; Candotti F; Otsu M; Sorrentino B; Scobie L; Cameron E; Blyth K; Neil J; Abina SH; Cavazzana-Calvo M; Fischer A
    Nature; 2006 Sep; 443(7109):E5-6; discussion E6-7. PubMed ID: 16988659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.